Physiological mechanisms of dyspnea relief following ivacaftor in cystic fibrosis: A case report

Respiratory Physiology and Neurobiology

Volumn 205, Issue , 2015, Pages 105-108

  Quon, Bradley S ^a   Schaeffer, Michele R ^a   Molgat Seon, Yannick ^a   Wilkie, Sabrina S ^a   Wilcox, Pearce G ^a   Guenette, Jordan A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cystic fibrosis; Dyspnea; Ivacaftor

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; AMINOPHENOL DERIVATIVE; QUINOLONE DERIVATIVE;

ARTICLE; CARDIOPULMONARY EXERCISE TEST; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DYSPNEA; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENE MUTATION; INSPIRATORY RESERVE VOLUME; LUNG FUNCTION; PRIORITY JOURNAL; TOTAL LUNG CAPACITY; ADULT; CASE REPORT; COMPLICATION; DRUG EFFECTS; HUMAN; LUNG FUNCTION TEST; MALE; RESPIRATORY FUNCTION;

ADULT; AMINOPHENOLS; CYSTIC FIBROSIS; DYSPNEA; EXERCISE TOLERANCE; HUMANS; MALE; QUINOLONES; RESPIRATORY FUNCTION TESTS; RESPIRATORY PHYSIOLOGICAL PHENOMENA;

EID: 84922928641     PISSN: 15699048     EISSN: 18781519     Source Type: Journal    
DOI: 10.1016/j.resp.2014.10.019     Document Type: Article

References (10)

1. American Thoracic Society, Amercian College of Chest Physicians ATS/ACCP statement on cardiopulmonary exercise testing. Am. J. Respir. Crit. Care Med. 2003, 167:211-277.
2. Davies J.C., Wainwright C.E., Canny G.J., Chilvers M.A., Howenstine M.S., Munck A., Mainz J.G., Rodriguez S., Li H., Yen K., Ordonez C.L., Ahrens R. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am. J. Respir. Crit. Care Med. 2013, 187:1219-1225.
3. Guenette J.A., Dominelli P.B., Reeve S.S., Durkin C.M., Eves N.D., Sheel A.W. Effect of thoracic gas compression and bronchodilation on the assessment of expiratory flow limitation during exercise in healthy humans. Respir. Physiol. Neurobiol. 2010, 170:279-286.
4. Harrison M.J., Murphy D.M., Plant B.J. Ivacaftor in a G551D homozygote with cystic fibrosis. N. Engl. J. Med. 2013, 369:1280-1282.
5. Hoare S., McEvoy S., McCarthy C.J., Kilcoyne A., Brady D., Gibney B., Gallagher C.G., McKone E.F., Dodd J.D. Ivacaftor imaging response in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2014, 189:484.
6. Laveneziana P., Bruni G.I., Presi I., Stendardi L., Duranti R., Scano G. Tidal volume inflection and its sensory consequences during exercise in patients with stable asthma. Respir. Physiol. Neurobiol. 2013, 185:374-379.
7. Laveneziana P., Webb K.A., Ora J., Wadell K., O'Donnell D.E. Evolution of dyspnea during exercise in chronic obstructive pulmonary disease: impact of critical volume constraints. Am. J. Respir. Crit. Care Med. 2011, 184:1367-1373.
8. O'Donnell D.E., Guenette J.A., Maltais F., Webb K.A. Decline of resting inspiratory capacity in COPD: the impact on breathing pattern, dyspnea, and ventilatory capacity during exercise. Chest 2012, 141:753-762.
9. O'Donnell D.E., Ora J., Webb K.A., Laveneziana P., Jensen D. Mechanisms of activity-related dyspnea in pulmonary diseases. Respir. Physiol. Neurobiol. 2009, 167:116-132.
10. Ramsey B.W., Davies J., McElvaney N.G., Tullis E., Bell S.C., Drevinek P., Griese M., McKone E.F., Wainwright C.E., Konstan M.W., Moss R., Ratjen F., Sermet-Gaudelus I., Rowe S.M., Dong Q., Rodriguez S., Yen K., Ordonez C., Elborn J.S. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 2011, 365:1663-1672.